Trevi Therapeutics, Inc. (NASDAQ:TRVI) Short Interest Update

Trevi Therapeutics, Inc. (NASDAQ:TRVI) was the target of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 4,660,000 shares, a growth of 230.5% from the November 30th total of 1,410,000 shares. Based on an average daily trading volume, of 1,660,000 shares, the short-interest ratio is currently 2.8 days.

Analysts Set New Price Targets

A number of equities analysts have issued reports on TRVI shares. Needham & Company LLC reissued a “buy” rating and issued a $8.00 target price on shares of Trevi Therapeutics in a report on Thursday, December 12th. Leerink Partnrs raised Trevi Therapeutics to a “strong-buy” rating in a report on Monday, September 9th. B. Riley reiterated a “buy” rating and issued a $6.00 target price on shares of Trevi Therapeutics in a research note on Monday, October 7th. HC Wainwright boosted their price target on shares of Trevi Therapeutics from $6.00 to $7.50 and gave the company a “buy” rating in a report on Thursday, December 12th. Finally, Raymond James assumed coverage on shares of Trevi Therapeutics in a report on Friday, August 30th. They issued an “outperform” rating and a $9.00 price objective on the stock. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $9.31.

Trevi Therapeutics Trading Up 1.4 %

TRVI traded up $0.06 on Friday, reaching $4.27. The company had a trading volume of 757,357 shares, compared to its average volume of 617,921. The company has a market capitalization of $328.22 million, a P/E ratio of -9.70 and a beta of 0.96. The company has a fifty day moving average of $3.20 and a 200-day moving average of $3.04. Trevi Therapeutics has a one year low of $1.27 and a one year high of $4.68.

Trevi Therapeutics (NASDAQ:TRVI) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). During the same quarter last year, the company posted ($0.08) EPS. Research analysts predict that Trevi Therapeutics will post -0.49 EPS for the current year.

Hedge Funds Weigh In On Trevi Therapeutics

Hedge funds have recently modified their holdings of the company. Ally Bridge Group NY LLC bought a new stake in shares of Trevi Therapeutics during the 2nd quarter worth $4,395,000. Logos Global Management LP raised its holdings in Trevi Therapeutics by 27.3% during the 2nd quarter. Logos Global Management LP now owns 2,800,000 shares of the company’s stock worth $8,344,000 after buying an additional 600,000 shares during the period. GSA Capital Partners LLP purchased a new stake in Trevi Therapeutics during the third quarter valued at about $409,000. Geode Capital Management LLC boosted its holdings in shares of Trevi Therapeutics by 10.2% in the third quarter. Geode Capital Management LLC now owns 1,264,166 shares of the company’s stock worth $4,223,000 after buying an additional 117,418 shares during the period. Finally, Fred Alger Management LLC purchased a new position in shares of Trevi Therapeutics in the third quarter worth approximately $256,000. 95.76% of the stock is currently owned by institutional investors and hedge funds.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.